Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced plans to advance its TEV-’408, an investigational anti-interleukin-15 monoclonal antibody, into a Phase 2b study in vitiligo in the fourth quarter of 2026. The decision follows encouraging results from an ongoing Phase 1b, open-label study in adults with active or stable non-segmental vitiligo (NSV).

Data from the ongoing, open-label Phase 1b study showed improvements in skin pigmentation in patients with active or stable NSV. TEV-’408 was well-tolerated with no safety signals observed to date. At baseline, 66% of enrolled participants had vitiligo affecting more than 10% of body surface area, representing a population with limited treatment options. At week 24, in evaluable participants:

  • Nearly 75% of patients reported improvement in facial vitiligo, with half reporting "much" or "very much" improved
  • 42% achieved F-VASI50 and 21% achieved F-VASI75
  • 55% of patients reported improvement in total body vitiligo
  • 7% achieved T-VASI50

"TEV-’408 exemplifies the type of innovative, Teva-discovered program we are prioritizing as we continue to advance and strengthen our immunology pipeline," said Richard Francis, President and Chief Executive Officer of Teva. "Grounded in compelling biology and focused on meaningful unmet need, TEV-’408 reflects our progress in our Pivot to Growth strategy and our commitment to pursuing differentiated innovation for patients."

Vitiligo is a chronic autoimmune disease that causes loss of skin pigmentation and can have a significant impact on quality of life, self-image, and daily social interactions. Despite recent advances, treatment options remain limited, particularly for patients with more extensive disease, who may require systemic therapy, or those seeking better disease control.

"Vitiligo can affect far more than the skin. It can shape how people see themselves, how they show up in the world, and the confidence they carry every day," said Eric Hughes, MD, PhD, Executive Vice President, Global R&D and Chief Medical Officer at Teva. "These encouraging data strengthen our confidence in the IL-15 pathway and reflect the depth of Teva’s scientific expertise. We are excited by the potential of this program to offer a meaningful new option for people living with vitiligo."